Messy megamergers

Last week, there were reports in the Financial Times and elsewhere of talks between AstraZeneca (AZ) and Bristol Myers Squibb (BMS) over the possibility of a merger deal. This week, continued reporting suggests that – while there had been discussions – the plan was quashed by shareholder objections.